Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 12:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Non-insulin anti-diabetic treatment Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin icodec, Insulin glargine; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 984 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 97
States / cities: Birmingham, Alabama • Guntersville, Alabama • Little Rock, Arkansas + 85 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin glargine, 300U/mL, Insulin degludec, 100 U/mL, Non-insulin anti-diabetic treatment; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 929 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 74
States / cities: Sheffield, Alabama • Phoenix, Arizona • Anaheim, California + 62 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin detemir, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 20
States / cities: Fresno, California • Mission Viejo, California • Miami, Florida + 15 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Insulin Glargine (HOE901 - U300), Insulin Glargine (HOE901 - U100), Background therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 65 Years and older
Enrollment: 1,014 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 64
States / cities: Saraland, Alabama • Fresno, California • Greenbrae, California + 57 more

Conditions: Obesity, Insulin Resistance
Interventions: Fat biopsy during scheduled abdominal surgery, Fat Aspiration, Fish Oil Supplement; Procedure · Dietary Supplement
Lead sponsor: Mayo Clinic; Other
Eligibility: 30 Years to 50 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Diabetes Mellitus
Interventions: Oral Anti-diabetes Drugs alone, Basal bolus insulin, Supplemental insulin, Continuous glucose monitoring (CGM); Drug · Device
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes, Mitochondrial Metabolism Disorders
Interventions: Pioglitazone, Placebo; Drug · Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: San Antonio, Texas

Conditions: Cushing's Disease, Acromegaly
Interventions: Pasireotide s.c., Sitagliptin, Liraglutide, Insulin, Pasireotide LAR, Metformin; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 15
States / cities: Multiple Locations, California • Torrance, California • Ventura, California + 10 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin degludec, Insulin Icodec; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Not listed
Enrollment: 526 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 38
States / cities: Buena Park, California • Encino, California • Fresno, California + 32 more

Conditions: Type 2 Diabetes
Interventions: Lixisenatide (AVE0010), Placebo, Antidiabetic background therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 70 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 14
States / cities: La Jolla, California • Norwalk, California • Miami, Florida + 10 more

Conditions: Type 2 Diabetes
Interventions: Linagliptin, Basal Bolus, Linagliptin + 50% Glargine dose on discharge, Linagliptin + 80% Glargine; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 5
States / cities: Denver, Colorado • Atlanta, Georgia • Chicago, Illinois + 1 more

Conditions: Type 2 Diabetes, Diabetes
Interventions: Salsalate, Placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin Glargine, Sitagliptin, Metformin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 35 Years to 70 Years
Enrollment: 515 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Type 1 Diabetes, Type 2 Diabetes
Interventions: Technosphere Insulin Inhalation Powder, Comparator; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 649 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 109
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 77 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin Glargine, Sitagliptin, Metformin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 35 Years to 71 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Search by objective public record fields.

A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before

Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist

Comparison of the Blood Sugar Lowering Effect and Safety of Two Insulin Treatments in Type 2 Diabetes

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications

Understanding the Relationship Between Inflammation and Insulin Resistance in the Adipose Tissue

Oral Anti Diabetic Agents in the Hospital

Quantifying Hepatic Mitochondrial Fluxes in Humans

Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly

A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin

Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients

Linagliptin Inpatient Trial

The Effects of Anti-Inflammatory Treatment on Insulin Resistance in Healthy Volunteers

Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-naive Patients

A 2-Month Safety Follow-Up Trial

Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial